GlassScriptPhysician profile
Cesar C Santos
NPI 1851377790
$15,911.89
in general payments reported to CMS, 2019-2025
44 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,454 · 2020: $2,432 · 2021: $1,261 · 2022: $1,244 · 2023: $1,306 · 2024: $1,753 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,520.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $7,278.44 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $1,144.74 | 2020-2025 | Valtoco |
| Ucb, INC. | $1,080.90 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Ptc Therapeutics, INC. | $505.21 | 2019-2024 | Emflaza |
| Ipsen Biopharmaceuticals, INC | $441.08 | 2019-2025 | Dysport |
| Eisai INC. | $438.08 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $382.86 | 2019-2022 | |
| Greenwich Biosciences, INC. | $377.55 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $361.90 | 2022-2025 | Epidiolex |
| Neuropace, INC. | $304.23 | 2020-2025 | |
| Biogen, INC. | $261.98 | 2020-2025 | Spinraza, Skyclarys |
| Catalyst Pharmaceuticals, INC. | $246.06 | 2023-2025 | Fycompa |
| Novartis Pharmaceuticals Corporation | $232.32 | 2019-2024 | |
| Genentech USA, INC. | $224.68 | 2021-2025 | Evrysdi |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $199.18 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.